Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions

Journal of Pathology

Volumn 179, Issue 3, 1996, Pages 260-265

  De Vries, Teunis J ^a   De Wit, Peter E J ^a   Clemmensen, Inge ^b   Verspaget, Hein W ^c   Weidle, Ulrich H ^d   Bröcker, Eva B ^e   Ruiter, Dirk J ^a   Van Muijen, Goos N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AGILENT TECHNOLOGIES   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

co localization; immunohistochemistry; melanoma; plasminogen; plasminogen activation; skin; tetranectin

Indexed keywords

PLASMIN; PLASMINOGEN; TETRANECTIN; UROKINASE;

ARTICLE; CANCER PATIENT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL; SKIN TUMOR; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 0029813008     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO;2-T     Document Type: Article

References (32)

1. Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191-217.
2. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
3. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
4. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 50: 273-328.
5. Quax PHA, Pedersen N, Masucci MT, et al. Complementation of urokinase and its receptor in extracellular matrix degradation. Cell Regulation 1991; 2: 793-803.
6. Pyke C, Kristensen P, Ralfkiær E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-1067.
7. Römer J, Pyke C, Lund LF, et al. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 1994; 57: 553-560.
8. De Vries TJ, Quax PHA, Denijn MD, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
9. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-111.
10. Delbaldo C, Masouye I, Saurat J-H, Vassalli J-D, Sappino A-P. Plasminogen activation in melanocytic neoplasia. Cancer Res 1994; 54: 4547-4552.
11. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986; 156: 327-333.
12. Jensen BA, Clemmensen I. Plasma tetranectin is reduced in cancer and related metastases. Cancer 1988; 62: 3222-3227.
13. Nielsen H, Clemmensen I, Nielsen HJ, Drivsholm A. Decreased tetranectin in multiple myeloma. Am J Hematol 1990; 33: 142-144.
14. Høgdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 1993; 72: 2415-2422.
15. Nielsen H, Clemmensen I, Kharazmi A. Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol 1993; 37: 39-42.
16. Borregaard N, Christensen L, Bjerrum OW, Birgens HS, Clemmensen I. Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contain tetranectin and latent alkaline phosphatase. J Clin Invest 1990; 85: 408-416.
17. Clemmensen I, Lund LF, Christensen L, Andreasen P. A tetranectin-related protein is produced and deposited in extracellular matrix by human fibroblasts. Eur J Biochem 1991; 195: 735-741.
18. Christensen L, Clemmensen I. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 1991; 95: 427-433.
19. Wewer U, Albrechtsen R. Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer. Lab Invest 1992; 67: 253-262.
20. Verspaget HW, Clemmensen I, Ganesh S, et al. Tetranectin expression in human colonic neoplasia. Histopathology 1994; 25: 463-467.
21. Burtin P, Chavanel G, Andre J. The plasmin system in human colonic tumors: an immunofluorescence study. Int J Cancer 1985; 35: 307-314.
22. Christensen L, Clemmensen I. Tetranectin immunoreactivity in normal human tissues. Histochemistry 1989; 92: 29-35.
23. Sontheimer RD. Perivascular dendritic macrophages as immunobiological constituents of the human dermal microvascular unit. J Invest Dermatol 1989; 93 (2, Suppl): 96S-101S.
24. Salonen E-M, Saksela O, Vartio T, Vaheri A, Nielsen LS, Zeuthern J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem 1986; 260: 12302-12307.
25. Salonen E-M, Zitting A, Vaheri A. Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett 1984; 172: 29-32.
26. Stack MS, Moser TL, Pizzo SV. Binding of human plasminogen to basement membrane (type IV) collagen. Biochem J 1992; 284: 103-108.
27. Kost C, Stüber W, Ehrlich HJ, Pannekoek H, Preissner KT. Mapping of binding sites for heparin, plasminogen activator inbibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 1992; 267: 12098-12105.
28. Burtin P, Fondaneche MC. Receptor for plasmin on human carcinoma cells. J Natl Cancer Inst 1988; 80: 762-765.
29. Burtin P, Zhang S, Schauffler J, Komano O, Sastre X, Mathieu MC. Visualization of the plasmin receptor on sections of human mammary carcinoma cells. Int J Cancer 1993; 53: 17-21.
30. De Vries TJ, Mooy CM, Van Balken MR, et al. Components of the plasminogen activation system in uveal melanoma - a clinico-pathological study. J Pathol 1995; 175: 59-67.
31. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993; 82: 2433-2441.
32. Zhang S, Laurent M, Lopez-Alemany R, et al. Comparative localization of receptors for plasmin and for urokinase on MCF7 cells. Exp Cell Res 1993; 207: 290-299.